Cutera

Cutera, Inc. engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cutera reports strong 2022 performance with focus on AviClear growth

Cutera's performance in 2022 showcased resilience and growth potential, driven by the successful AviClear launch. While facing revenue challenges in Q4 2022, the company is optimistic about achieving cash flow breakeven by Q4 2023. With a bullish outlook for 2023, Cutera aims to leverage its core business strength and accelerate AviClear sales.

Cutera reports Q1 revenue dip, focuses on AviClear growth

Cutera faces challenges in North American sales but sees growth opportunities internationally and with AviClear devices.
Financials show a loss in adjusted EBITDA and decreased cash, but the company is focused on improving execution and driving utilization rates.
Retention incentives have been effective, and steps are being taken to enhance performance and return to sustainable growth.

Cutera reports Q2 revenue decline, focuses on AviClear performance

Cutera reported Q2 2023 revenue of $61.2 million, down 5% YoY, with an adjusted EBITDA loss of $11.6 million. The company is focusing on AviClear performance, quality control, and core business growth.
Challenges include declining core capital business, operational issues, and macroeconomic challenges. Opportunities lie in optimizing AviClear utilization, enhancing reliability, and introducing new products for growth.
Cutera's commitment to addressing challenges, enhancing service levels, and executing a strategic plan for sustainable growth is evident. The organization is resilient in the face of macroeconomic pressures and is adapting its strategies for success.
Retention bonuses, successful employee retention, and efforts to improve quality control measures demonstrate Cutera's internal strengths. The company's strategic approach to product lines and growth showcases a positive outlook for the future.

Cutera reports Q3 revenue decline, focuses on cost reduction

Cutera faces revenue decline and operational challenges in Q3 2023, impacting full-year guidance. Plans for cost reduction, growth strategies, and personnel restructuring in progress. Positive outlook for achieving financial goals with confidence.

Cutera reports Q4 revenue growth, focuses on AviClear expansion

Cutera's Q4 performance reflects resilience with better-than-anticipated revenue and stable AviClear revenue.
Focus on operational excellence, global franchise building, and customer support positions Cutera for long-term success.
Efforts to address challenges like inventory management and customer adoption of new business models are crucial for growth.

Cutera reports mixed Q1 results, focuses on AviClear growth

Cutera's Q1 performance showed a revenue decline but growth in AviClear revenue, with a focus on operational excellence and building a strong AviClear franchise. The company faces challenges with declining customer site volumes and an uncertain timeline for patient demand. However, opportunities exist in international expansion, R&D innovation, and addressing future market needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cutera has flown under the radar in FY22 after collapsing from 52-week highs back in April. Shares look unfairly compressed and have recently tested long-term resistance levels.

Cutera: Shares Very Attractively Priced, Top-Line Hedged From CMS

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announces that over 1,000 AviClear laser treatments have been performed in the United States. AviClear is the first and only energy-based device to be FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities of acne as well as th

Cutera Announces Over 1,000 AviClear™ Acne Treatments Performed

Cutera, Inc. (NASDAQ:CUTR ) Q2 2022 Results Conference Call August 4, 2022 4:15 PM ET Company Participants Dave Mowry - CEO Rohan Seth - CFO Conference Call Participants Jon Block - Stifel Chris Cooley - Stephens Louise Chen - Cantor Operator Thank you for joining Cutera's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] The discussion today includes forward-looking statements.

Cutera, Inc. (CUTR) CEO Dave Mowry on Q2 2022 Results - Earnings Call Transcript

Cutera (CUTR) delivered earnings and revenue surprises of -9.09% and 0.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cutera (CUTR) Reports Q2 Loss, Lags Revenue Estimates

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial and Operational Highlights Consolidated revenue of $64.2 million driven by strength in capital equipment and consumable product demand. Over 50 AviClear devices were placed and activated during the first quarter of the product's limited comm

Cutera Announces Second Quarter 2022 Financial Results

Arch Resources

EVgo

eXp World Holdings Inc

SunPower

Stocks continue to trend higher with the S&P 500 trading near a 3-month high. We are bullish and expect more upside into what could be an accelerating market-wide short squeeze.

Bears Have Been Shooting Bricks For 3 Months - Buy These 5 Short Squeeze Ideas

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the second quarter after the market close on Thursday, August 4, 2022. The Company's management will host a conference call to discuss these results and related matters at 1:15 p.m. PT (4:15 p.m. ET) that same day. To join the conference call, dial 1-800-319-4610 (domestic) or +1-631-891-4

Cutera, Inc. to Announce Second Quarter Results on August 4, 2022

TORONTO--(BUSINESS WIRE)--Health Canada Clears Cutera's AviClear™; The First and Only Device in North America Cleared for the Treatment of Mild, Moderate and Severe Acne

Health Canada Clears Cutera's AviClear™

Cutera has received an FDA clearance for the first and only laser-based acne treatment representing a significant market opportunity. The company last reported its Q1 results in May, highlighted by solid sales momentum from its existing skin revitalization and body sculpting products portfolio.

Cutera: The 'AviClear' Sign To Get Bullish

BRISBANE, Calif.--(BUSINESS WIRE)--Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, including AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne that is now being made available in a

New Research Reveals Roughly 4 in 5 Moderate to Severe Acne Sufferers Have Missed Moments in Their Life Due to Acne

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced the pricing of $210 million aggregate principal amount of 2.25% convertible senior notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) (the “Rule 144A Offering”) and a separate concurrent private placem

Cutera, Inc. Announces Pricing of Offering of $200 Million and Concurrent Private Placement of $10 Million of Convertible Senior Notes

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and in a sepa

Cutera, Inc. Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

Cutera, Inc. (NASDAQ:CUTR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dave Mowry – Chief Executive Officer Rohan Seth – Chief Financial Officer Conference Call Participants Jon Block – Stifel Chris Cooley – Stephens Louise Chen – Cantor Anthony Vendetti – Maxim Group Operator Thank you for joining Cutera's First Quarter 2022 Earnings Conference Call. After the prepared remarks, there will be a question-and-answer session.

Cutera's (CUTR) CEO Dave Mowry on Q1 2022 Results - Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial and Operational Highlights Revenue was $58.0 million, an increase of 17% from the prior-year period as reported and 21% on a constant currency basis, driven by robust performance across the business, with particular strength in North America;

Cutera Announces Record First Quarter 2022 Revenue Results

Here is how Cutera (CUTR) and Jack Henry (JKHY) have performed compared to their sector so far this year.

Has Cutera (CUTR) Outpaced Other Computer and Technology Stocks This Year?

BRISBANE, Calif.,--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that clinical data related to AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne; was presented during the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS) which took place from April 27-30 in San Diego, CA. AviClear's 1726 nm laser was highlighted thro

Cutera's AviClear™ Clinical Data Presented at the Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS)

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter of 2022 after the market close on Tuesday, May 10, 2022. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m. ET) that same day. To join the conference call, dial 1-800-381-7839 (domestic) or +1-416-9

Cutera, Inc. to Announce First Quarter Results on May 10, 2022

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cutera (CUTR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why "Trend" Investors Would Love Betting on Cutera (CUTR)

Synchrony Financial

BRISBANE, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a leading provider of dermatological solutions, and Synchrony (NYSE: SYF), a leading provider of consumer payment and financing solutions, today announce an exclusive partnership to expand patient financing options to dermatology practices across the United States. Cutera's AviClear is the first and only device cleared by the FDA for the treatment of mild, moderate and severe acne. Dermatologists offering AviClear

Cutera Partners with Synchrony to Provide Financing Options to Dermatology Patients for Innovative New Acne Treatment

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced that the first patient outside of clinical trials was treated with AviClear, the only device cleared by the FDA for the treatment of mild, moderate, and severe acne. AviClear received FDA 510k clearance on March 24, 2022, following the Company's successful product development process and extensive clinical evaluation. Designed with physician an

Cutera Announces First Patient Treated with FDA Cleared AviClear™ Acne Device

Cutera (CUTR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cutera (CUTR) Upgraded to Buy: Here's Why

The FDA has granted 510(k) clearance to Cutera Inc's (NASDAQ: CUTR) AviClear for acne. The Company notes that AviClear is the first and only energy-based device to receive this designation to treat mild, moderate, and severe acne.

Why Cutera's Shares Are Soaring Today

BRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of dermatology solutions, today announced the U.S. Food and Drug Administration's 510(k) clearance of AviClear, the first and only energy-based device to receive this designation for the treatment of mild, moderate, and severe acne. AviClear is a laser treatment that offers a safe, prescription-free solution for acne.1 In addition to reducing existing acne, clinical trials show that fu

FDA Clears Cutera's AviClear™ Acne Device

BRISBANE, Calif.--(BUSINESS WIRE)--Cutera, Inc. (NASDAQ: CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will participate in the Aesthetic Device Industry Panel at the Maxim Virtual Growth Conference at 1:00 p.m. ET on Monday, March 28, 2022. Investors may listen to the live event by registering for the conference at https://m-vest.com/events/2022-virtua

Cutera, Inc. to Participate in the Aesthetic Device Industry Panel at the Maxim Virtual Growth Conference

Cutera, Inc.'s (CUTR) CEO Dave Mowry on Q4 2021 Results - Earnings Call Transcript

News for Cutera Stock (CUTR)